Results

30 December, 2024

A new drug improves clinical outcomes for patients with advanced breast cancer

A Phase 3 clinical trial demonstrates that the combination of imlunestrant and abemaciclib improves progression-free survival in advanced ER+ HER2- breast cancer, regardless of genomic profile. The compound as monotherapy only shows benefits in patients with mutations in the ESR1 gene.
12 December, 2024

Aragonese partners of the AI4HealthyAging project present the results

The IIS Aragón, together with the IACS, the ITA, Podoactiva and BitBrain, presented the results of the project on Tuesday, December 10. The AI4HealthyAging initiative aims to prevent age-related neurodegenerative diseases through Artificial Intelligence.